Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

8.28
-0.1400-1.66%
Post-market: 8.420.1400+1.69%19:30 EDT
Volume:197.31K
Turnover:1.64M
Market Cap:141.63M
PE:-2.15
High:8.46
Open:8.38
Low:8.22
Close:8.42
52wk High:16.77
52wk Low:8.05
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.59
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:0.66
PE(LYR):-2.60

Loading ...

Circio Showcases circVec Data and Opens Discounted Warrant Exercise Window

TIPRANKS
·
May 28

MindWalk Holdings Launches AI-Driven Pandemic Response Platform for RNA Virus Outbreaks

TIPRANKS
·
May 27

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

TIPRANKS
·
May 27

Korro to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 27

Circio and AaviGen Join Forces on Next-Generation Heart-Targeted Gene Therapies

TIPRANKS
·
May 27

FACTBOX-Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Reuters
·
May 20

Blank Bio closes $7.2M seed financing, collaboration with Pacific Biosciences

TIPRANKS
·
May 19

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire
·
May 19

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

GlobeNewswire
·
May 19

Circio touts potent circRNA platform with dose-cutting promise at ASGCT

TIPRANKS
·
May 16

Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says

MT Newswires Live
·
May 16

Avidity Biosciences Initiated at Outperform by Leerink Partners

Dow Jones
·
May 16

Atrium Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
May 15

Atrium Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $25

THOMSON REUTERS
·
May 15

Corrected-Atrium Therapeutics Inc Q1 Operating Income USD -17.28 Million (Correct Source, Adds Ric)

THOMSON REUTERS
·
May 15

Corrected-Atrium Therapeutics Inc Q1 Operating Expenses USD 36.915 Million (Correct Source, Adds Ric)

THOMSON REUTERS
·
May 15

Atrium Therapeutics Q1 FY26 net loss widens to $16.63 million; revenue rises to $19.64 million

Reuters
·
May 15

Atrium Therapeutics Q1 collaboration revenue surges after spin-off

Reuters
·
May 15

Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate

Benzinga Earnings
·
May 15

Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

prnewswire
·
May 14